Boston Scientific Stock Falls Over Half Despite Rising Sales
Boston Scientific (BSX) has seen its stock price drop more than 54% since late December 2025, despite continued sales growth. The decline was driven by two major disappointments in the electrophysiology segment and a slowdown in WATCHMAN implant procedures. The first setback occurred on February 4, 2026, when U.S. electrophysics sales fell short of expectations, causing an 18% single-day drop. In July 2026, Boston Scientific cut its full-year revenue guidance to between 5% and 6%, citing challenges in the WATCHMAN business where stand-alone procedures declined while concomitant ones grew rapidly but are expected to slow. Despite these issues, three-quarters of the company's segments remain on track for steady growth. Total organic sales rose 7% in Q2 2026, and management anticipates limited adjusted EPS growth through 2027 with a restructuring program aimed at $500 million in savings by 2029.
Topics: electrophysiology sales growth vs. stock price stock decline WATCHMAN implant